Are you Dr. Harker?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 53 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3838 S 700 E
Suite 100
Salt Lake City, UT 84106Phone+1 801-269-0231Fax+1 801-269-0304
Summary
- Dr. William Harker, MD is an oncologist in Salt Lake City, Utah. He is currently licensed to practice medicine in Utah. He is affiliated with Intermountain Medical Center and Lakeview Hospital.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1980 - 1984
Johns Hopkins UniversityResidency, Internal Medicine, 1975 - 1978
University of Utah School of MedicineClass of 1975
Certifications & Licensure
UT State Medical License 1984 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
Clinical Trials
- S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo Start of enrollment: 2006 Oct 01
- S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma Start of enrollment: 2007 Jul 01
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Publications & Presentations
PubMed
- 109 citationsContinued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.Gabriel N. Hortobagyi, Catherine Van Poznak, W. Graydon Harker, William J. Gradishar, Helen K. Chew
JAMA Oncology. 2017-07-01 - 141 citationsFinal 5-year results of Z-FAST trial: Adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozoleAdam Brufsky, W. Graydon Harker, J. Thaddeus Beck, Linda D. Bosserman, Charles L. Vogel
Cancer. 2012-03-01 - 43 citationsDifferential immunohistochemical staining for DNA topoisomerase II alpha and beta in human tissues and for DNA topoisomerase II beta in non-Hodgkin's lymphomas.M E Bauman, Joseph A. Holden, Karen A. Brown, W G Harker, Sherrie L. Perkins
Modern Pathology. 1997-03-01
